| Business Summary | | Nymox
Pharmaceutical
Corporation
is
a
development
stage
biopharmaceutical
company.
The
Company
specializes
in
the
research
and
development
of
therapeutics
and
diagnostics
for
the
aging
population
with
an
emphasis
on
Alzheimer's
disease.
The
Company
markets
a
proprietary
diagnostic
test
for
Alzheimer's
disease,
known
as
the
AlzheimAlert
Test,
through
its
reference
laboratory
in
Maywood,
New
Jersey.
AlzheimAlert
is
an
improved
version
of
the
Company's
AD7C
test,
which
has
been
on
the
market
since
1997.
AlzheimAlert
is
the
latest
generation
of
the
Company's
NTP
testing
technology.
It
measures
the
level
of
a
brain
protein
called
neural
thread
protein
(NTP),
which
is
elevated
early
in
Alzheimer's
disease
as
reported
both
in
the
scientific
literature
and
at
scientific
conferences. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | NYMX
is
a
development
stage
biopharmaceutical
company
which
specializes
in
the
research
and
development
of
neurological
therapeutics
and
diagnostics
for
the
aging
population,
with
emphasis
on
Alzheimer's
disease.
For
the
six
months
ended
6/30/01,
total
revenues
totalled
$229
thousand,
up
from
$108
thousand.
Net
loss
from
U.S.
GAAP
decreased
35%
to
$1.3
million.
Revenues
reflect
an
increase
in
sales
of
diagnostic
services.
Lower
loss
reflects
a
decrease
in
salary
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY1999 Pay | |
| W. David Angus, 62 Chairman | -- | Paul Averback, M.D., 49 Pres,
CEO | $104K | Allan Reimer, Ph.D. VP,
Technology Acquisition and Devel. | -- | Roy Wolvin, 45 Sec.,
Treasurer, CFO | 49K | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|